#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14134	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2134	658.7	0	.	n	.	0	A69G	SNP	69	69	A	328	328	G	739	G,A,T	691,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14134	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2134	658.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1709	1709	T	777	T,C	714,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14134	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2134	658.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1443	1443	C	856	C	797	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25966	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3608	717.9	0	.	n	.	0	T695C	SNP	695	695	T	1043	1043	C	752	C,T	706,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25966	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3608	717.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2319	2319	C	821	C	760	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25966	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3608	717.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2945	2945	T	791	T	749	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25966	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3608	717.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2393	2393	A	877	A	826	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2144	folP	855	855	100.0	folP.l15.c4.ctg.1	1566	136.3	1	SNP	p	R229S	1	.	.	685	687	AGC	997	999	AGC	223;223;224	A;G;C	206;207;204	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6004	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3480	172.1	1	SNP	p	S91F	1	.	.	271	273	TTC	630	632	TTC	216;217;212	T;T,C;C	205;203,2;202	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6004	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3480	172.1	1	SNP	p	G95N	0	.	.	283	285	GGC	642	644	GGC	209;205;208	G;G,A;C	191;185,2;190	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6004	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3480	172.1	1	SNP	p	D95G	1	.	.	283	285	GGC	642	644	GGC	209;205;208	G;G,A;C	191;185,2;190	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1688	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1340	125.7	0	.	p	.	0	D79N	NONSYN	235	237	GAT	569	571	AAT	206;208;206	A;A;T	192;192;191	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1688	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1340	125.7	1	SNP	p	G45D	0	.	.	133	135	GGC	467	469	GGC	196;195;196	G;G;C	185;180;185	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	868	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	959	90.1	0	.	n	.	0	A197.	DEL	197	197	A	532	532	A	214	A	206	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5078	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2832	178.5	0	.	p	.	0	E91G	NONSYN	271	273	GAG	531	533	GGG	200;195;197	G;G;G	191;185;184	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5078	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2832	178.5	1	SNP	p	D86N	0	.	.	256	258	GAC	516	518	GAC	196;193;196	G;A;C	192;190;191	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5078	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2832	178.5	1	SNP	p	S87R	0	.	.	259	261	AGT	519	521	AGT	194;196;201	A;G;T	189;191;195	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5078	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2832	178.5	1	SNP	p	S87I	0	.	.	259	261	AGT	519	521	AGT	194;196;201	A;G;T	189;191;195	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5078	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2832	178.5	1	SNP	p	S87W	0	.	.	259	261	AGT	519	521	AGT	194;196;201	A;G;T	189;191;195	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5078	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2832	178.5	1	SNP	p	S88P	0	.	.	262	264	TCC	522	524	TCC	202;203;205	T;C;C	197;198;197	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4572	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2580	176.4	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1536	1538	CAC	222;219;220	C;A;C	209;203;204	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4572	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2580	176.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1485	1487	GGC	223;219;217	G;G;C	208;206;198	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1186	1188	GCA	222;225;228	G;C;A	209;213;218	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1189	1191	ATC	226;227;228	A;T;C	214;212;214	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1201	1203	GTG	237;237;235	G;T;G	221;222;220	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1201	1203	GTG	237;237;235	G;T;G	221;222;220	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1705	1707	ACC	219;220;220	A;C;C	206;207;207	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1759	1761	ACG	201;202;201	A;C,A;G	159;163,2;158	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1759	1761	ACG	201;202;201	A;C,A;G	159;163,2;158	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1882	1884	GGC	184;181;181	G;G;C	173;168;168	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1891	1893	GGC	180;180;183	G;G;C	163;161;163	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4000	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2381	167.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1909	1911	CTG	177;177;174	C,G;T;G	139,3;136;143	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5780	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2996	192.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1609	1611	CCG	201;201;201	C;C;G	180;186;177	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2582	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1752	146.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	506	506	C	193	C	177	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	0	.	p	.	0	T26A	NONSYN	76	78	ACC	378	380	GCC	213;212;210	G;C;C	203;204;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	414	416	GAA	230;232;232	G;A;A	220;224;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	0	.	p	.	0	N124S	NONSYN	370	372	AAT	672	674	AGT	214;214;216	A;G,A;T	204;201,1;204	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	702	704	GAT	225;227;229	G;A;T	217;219;217	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	825	827	TCA	206;206;212	T;C;A	196;199;204	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	0	.	p	.	0	A218I	NONSYN	652	654	GCC	954	956	ATC	235;233;235	A;T;C	219;213;220	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	0	.	p	.	0	F222L	NONSYN	664	666	TTT	966	968	CTT	222;224;223	C;T;T	209;213;212	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1284	1286	GCA	210;211;213	G;C;A	200;201;201	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	1	SNP	p	G120K	1	.	.	358	360	AAG	660	662	AAG	219;218;219	A;A;G	209;210;209	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	1	SNP	p	A121D	1	.	.	361	363	GAC	663	665	GAC	219;219;220	G,A;A;C	205,1;205;210	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1494	177.5	1	SNP	p	D121N	0	.	.	361	363	GAC	663	665	GAC	219;219;220	G,A;A;C	205,1;205;210	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9914	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4886	202.5	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1982	1984	CAT	217;215;217	C;A;T	204;203;203	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1080	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1073	100.3	1	SNP	p	V57M	1	.	.	169	171	ATG	615	617	ATG	220;218;218	A;T;G	207;205;204	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
